Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Sep;32 Suppl 2(Suppl 2):27-31.

Current status of ESKAPE microorganisms in Spain: Epidemiology and resistance phenotypes

J Sánchez-López, R Cantón  1
Affiliations
Review

Current status of ESKAPE microorganisms in Spain: Epidemiology and resistance phenotypes

J Sánchez-López et al. Rev Esp Quimioter. 2019 Sep.

Abstract

Resistance rates in ESKAPE microorganisms included in the EARS-net surveillance database from Spain have increased in most of the cases. In 2017, multi-drug resistant isolates rose to 5.5% in Escherichia coli and 13.0% in Klebsiella pneumoniae. Carbapenemase producing Enterobacterales (CPE) have also increased in Spain over the last years with a current spread of throughout the country. EuSCAPE project revealed dominance of OXA-48 carbapenemase with lower prevalence of KPC, VIM or NDM enzymes. Increase of faecal carriers and presence of carbapenemases in the so-called high-risk clones have boosted the persistence and dissemination of CPE. One of these clones, the ST307 K. pneumoniae, has been associated with the spread of KPC carbapenemases and emergence of KPC variants conferring resistance to ceftazidime-avibactam combination.

PubMed Disclaimer

Conflict of interest statement

Authors have no conflicts of interest to declare with respect to the contents of this manuscript.

Figures

Figure 1
Figure 1
Percentage of non-susceptible ESKAPE isolates. Data obtained from the EARS-net data base (https://ecdc.europa.eu/en/antimicrobial-resistance/surveillance-and-disease-data/data-ecdc, access February 2019)
Figure 2
Figure 2
Occurrence of different carbapenemases in carbapenemase-producing Klebsiella pneumoniae in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE) (Data obtained from reference [6])
See this image and copyright information in PMC

References

    1. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. J Infect Dis 2008;197:1079–81. doi:10.1086/533452. - DOI - PubMed
    1. Benjamin DK, Gilbert D, Bonomo RA, Jones RN, Talbot GH, Brad-ley J, et al. . 10 x ’20 Progress--Development of new drugs active against Gram-negative bacilli: An update from the Infectious Diseases Society of America. Clin Infect Dis 2013;56:1685–94. doi:10.1093/cid/cit152. - DOI - PMC - PubMed
    1. World Health Organization Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline, including tuberculosis. 2017. (WHO/EMP/IAU/2017.12). Licence: CC BY-NC-SA 3.0 IGO.
    1. Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) Registro hospitalario de pacientes afectados por las resistencias bacterianas. 2018. Available at: https://seimc.org/contenidos/noticias/2018/seimc-Registro_de_Pacientes_B....
    1. European Centre for Disease Prevention and Control Surveillance of antimicrobial resistance in Europe 2016, ECDC surveillance report. 2016. doi:10.2900/296939. - DOI

MeSH terms

Substances